MPO and colitis: In conclusion, our study demonstrates that Ax treatment significantly alleviates DSS-induced colitis, primarily by reducing MPO and proinflammatory mediators, protecting the intestinal barrier, modulating key gut microbiota, increasing beneficial bacterial populations, and inhibiting harmful bacteria.